MedTrace Logo

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-04-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate whether enoxaparin, minocycline, or both medications in combination may help in recovery from acute stroke.

Enoxaparin (brand name Lovenox®) is a medication approved for use in humans to prevent and to treat blood clots in deep veins in certain specific medical situations. Minocycline (brand name Minocin®) is a tetracycline antibiotic approved to treat a number of bacterial infections in humans. The investigators are studying these medications in acute human stroke because they have each been separately shown to reduce the amount of injured brain tissue in rats made to have acute ischemic stroke experimentally. In a human trial comparing minocycline with placebo (a sugar pill) acute ischemic stroke patients who took minocycline had better recovery after 1 week, 1 month and 3 months than patients who took placebo.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Enoxaparin

2 (or 3) intravenous doses, the first on study entry, the last 24 hours later

DRUG

Minocycline

200 mg orally once daily for 5 days

Sponsors & Collaborators

Principal Investigators

  • Saran Jonas, M.D. · Department of Neurology; New York University School of Medicine

  • Giacinto Grieco, M.D. · Department of Neurology; New York University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836355 on ClinicalTrials.gov